1 hour ago · China
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
What's happening
SignalsMonitor is following this as a markets story. South China Morning Post Asia is the outlet attached so far. The reports are tied to China. The first report grouped here was at 13 Nov 2026, 01:01 UTC. The headline in use is “Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug”. This note is SignalsMonitor's own briefing, not the publisher's article.
What we know
China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market. China’s National Medical Products Administration announced the approval on Thursday, saying that the once-daily pill, marketed…
Story timeline
Reports grouped into this story, earliest first. Exact repeats from the same outlet are collapsed.
- First reported by South China Morning Post Asia
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug
Reported by 1 outlet
- South China Morning Post
- South China Morning PostEli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug